USFDA concludes inspection at Zydus Lifesciences SEZ II, Ahmedabad plant
Ahmedabad: Zydus Lifesciences has announced that the US Food and Drug Administration (USFDA) has concluded inspection at the group’s formulation manufacturing plant located at SEZ – II, Ahmedabad with NIL observations.
The inspection was a Pre-Approval Inspection (PAI) for 3 products with general cGMP and was conducted from 11th to 13th August, 2025.
Zydus Lifesciences Ltd. is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R & D. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars.
Next Story